Sevoflurane-Remifentanil Anaesthesia. The Risk of Post Operative Nausea
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00452855|
Recruitment Status : Completed
First Posted : March 28, 2007
Last Update Posted : March 29, 2007
|Condition or disease||Intervention/treatment||Phase|
|Nausea Vomiting||Procedure: Sevoflurane-remifentanil anaesthesia||Not Applicable|
Propofol and sevoflurane anaesthesia are used world wide at the anaesthetists discretion.
Propofol is superior to inhalational anaesthetics as anaesthesia for patients at risk of post operative nausea and vomiting (PONV) as PONV is diminished. However, when remifentanil is used as adjuvant to sevoflurane, the total dose of the latter is reduced.
Therefore, we wanted to investigate if sevoflurane-remifentanil anaesthesia is similar to propofol-remifentanil anaesthesia with emphasis on nausea, vomiting and total PONV during 24 hours.
In the post anaesthesia care unit (PACU) and in the surgical ward nausea was scored on a visual analogue score. Vomiting was registered.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||160 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Postoperative Nausea and Vomiting Are Similar When Propofol or Sevoflurane Are Used as Adjuvant to Remifentanil During Anaesthesia for Gynaecological Surgery|
|Study Start Date :||January 2002|
|Actual Study Completion Date :||May 2005|
- Nausea, incidence and intensity ( VAS score )in PACU and surgical ward
- Vomiting, incidence in PACU and surgical ward
- Total PONV after 24 hours
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00452855
|Viborg, Denmark, 8800|
|Principal Investigator:||Jens Ole Dich JO Nielsen, MD|